Accelerating Drug Development through Repurposed FDA-Approved Drugs for COVID-19: Speed Is Important, Not Haste
- 22 July 2020
- journal article
- letter
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (8)
Abstract
A life-threatening, emerging respiratory disease called Coronavirus Disease 2019 (COVID-19) 26 originated in the city of Wuhan in China9s Hubei province in December, 2019 and has been classified as 27 an international pandemic by the World Health Organization.…Keywords
This publication has 25 references indexed in Scilit:
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- Compounds with Therapeutic Potential against Novel Respiratory 2019 CoronavirusAntimicrobial Agents and Chemotherapy, 2020
- Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquineInternational Journal of Antimicrobial Agents, 2020
- Pathological findings of COVID-19 associated with acute respiratory distress syndromeThe Lancet Respiratory Medicine, 2020
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clinical Infectious Diseases, 2020
- The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nature Microbiology, 2020
- In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirusJournal of Integrative Medicine, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Baricitinib as potential treatment for 2019-nCoV acute respiratory diseaseThe Lancet, 2020
- Animal models for SARS and MERS coronavirusesCurrent Opinion in Virology, 2015